May 9, 2017 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific’s Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with multisite pacing capability for multi-electrode pacing, and compatibility with the HeartLogic Heart Failure Diagnostic Service to help physicians improve heart failure (HF) management.

May 9, 2017 — The first patient has been enrolled in the U.S. Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door-to-Unloading (DTU) with Abiomed Impella CP percutaneous ventricular assist (pVAD) system in acute myocardial infarction.

May 9, 2017 — A manuscript by physicians from Mayo Clinic and Harvard Brigham & Women's Hospital entitled, “Initial Experience with the BioSig Pure EP Signal Recording System: An Animal Laboratory Experience,” was published in The Journal of Innovations in Cardiac Rhythm Management (JICRM), April 2017 issue. Read the article by clicking here.

Apple Watch used for tracking patient arrhythmias using an artificial intelligence-based algorithm

May 11, 2017 — A new study shows that the Apple Watch's heart rate sensor, when paired with an artificial intelligence-based algorithm, can detect a serious and often symptomless heart arrhythmia, atrial fibrillation (AF or aFib). The new research uses a deep neural network based on photoplethysmographic (PPG) sensors commonly found in smart watches. 
wearable defibrillators prevent sudden cardiac death in pediatric patients

May 11, 2017 — A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in treating ventricular arrhythmias for pediatric patients who are at risk for sudden cardiac death (SCD). The study represents the largest pediatric patient population to date when evaluating the WCD as a therapy option. The findings of the study were presented at Heart Rhythm 2017, the Heart Rhythm’s 38th Annual Scientific Sessions.
anticoagulants increase dementia risks

May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for atrial fibrillation (AFib or AF). The large study included more than 76,230 AF patients with no prior history of dementia that were treated with an antiplatelet or warfarin. The results were presented at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions, and show that warfarin, in particular, can increase the risk of dementia long-term.

May 12, 2017 – New study proves safety of novel, wireless pacing system, WiSE CRT (Wireless Stimulation Endocardially for cardiac resynchronization therapy) two years after implantation. The study is the first to report on the medium-long term feasibility of the EBR WiSE cardiac resynchronization therapy (CRT) leadless pacing system for heart failure patients and was presented at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions. 

International Conference for Innovations in Cardiovascular Systems (ICI)

Medtronic plc recently announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results were presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Bellevue, Wash., at the 2017 Charing Cross Symposium in London. The new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal closure system in treating patients with venous reflux disease.

May 5, 2017 — Northwell Health recently announced that Cindy Grines, M.D., one of the nation’s pre-eminent cardiologists, has joined Northwell Health, New York state’s largest healthcare provider and private employer. She also was appointed chair of cardiology at the Hofstra Northwell School of Medicine.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now